NCT07083960 - OM336 in Autoimmune Cytopenias | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

September 30, 2027

Conditions

AIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic AnemiaITP - Immune Thrombocytopenia

Interventions

DRUG

OM336

OM336 is an engineered bispecific antibody directed against BCMA and CD3

Trial Locations (3)

RECRUITING

Liverpool Hospital, Sydney

RECRUITING

The Canberra Hospital, Canberra

RECRUITING

Icon Cancer Center South Brisbane, Brisbane